GleamWall
中文EN

FLNA FILANA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$26.59M$69.64M
SG&A expense$68.80M$71.81M
Operating income-$95.39M-$141.45M
Income tax$0$0
Net income-$90.97M-$24.34M
EBITDA-$94.49M-$140.49M
EPS (basic)-1.88-0.53
EPS (diluted)-1.88-1.46
Weighted avg. shares (diluted)48.30M46.60M
Balance sheet
Cash & equivalents$95.50M$128.57M
Current assets$97.71M$136.53M
PP&E, net$20.65M$21.00M
Intangibles$193,000$37,000
Total assets$118.36M$157.53M
Current liabilities$43.83M$11.75M
Total liabilities$43.95M$11.83M
Shareholders' equity$74.40M$145.70M
Shares outstanding48.31M48.20M
Cash flow statement
Operating cash flow-$32.25M-$116.93M
Capital expenditure$581,000$103,000
Free cash flow-$32.83M-$117.03M
Investing cash flow-$581,000-$103,000
Financing cash flow-$239,000$124.47M
Depreciation & amortization$903,000$952,000
Stock-based compensation$19.58M$16.29M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.